Phospho-TOB1 (Ser164) Antibody

What is TOB1 and what is the significance of its phosphorylation at Ser164?

TOB1 is a 38 kDa protein belonging to the BTG/TOB family characterized by a BTG homology domain. It functions as a tumor suppressor by inhibiting cell proliferation through promoting mRNA deadenylation and negatively regulating Cyclin D1 expression . Human TOB1 shares approximately 96% amino acid sequence identity with mouse and rat orthologs, reflecting its evolutionary conservation .

Phosphorylation at Ser164 is a key regulatory mechanism that modulates TOB1's antiproliferative function. This post-translational modification appears to inhibit TOB1's tumor suppressor activity, potentially contributing to cancer progression. Research has shown that TOB1 is regulated by EGF-dependent HER2 and EGFR signaling pathways, and increased phosphorylation levels have been associated with poor prognosis in various cancers, including node-negative breast cancer and gastric cancer .

What applications can Phospho-TOB1 (Ser164) Antibody be used for?

Phospho-TOB1 (Ser164) Antibody can be employed in multiple research applications:

• Western Blotting (WB): Typically used at dilutions ranging from 1:500 to 1:2000, allowing detection and quantification of phosphorylated TOB1 in cell or tissue lysates .

• Immunohistochemistry (IHC): Recommended dilutions range from 1:100 to 1:300, enabling visualization of phosphorylated TOB1 in tissue sections and assessment of its subcellular localization .

• Immunofluorescence (IF): Generally used at dilutions of 1:50 to 1:200, facilitating detailed subcellular localization studies of phosphorylated TOB1 .

• ELISA: Typically used at higher dilutions (around 1:5000), allowing quantitative measurement of phosphorylated TOB1 levels .

• Cell-Based ELISA: Enables measurement of phosphorylated TOB1 in cultured cells without lysate preparation and facilitates screening of various treatments, inhibitors, or activators on TOB1 phosphorylation status .

The choice of application depends on your specific research question, sample type, and experimental design.

What species reactivity does the Phospho-TOB1 (Ser164) Antibody typically have?

Most commercially available Phospho-TOB1 (Ser164) Antibodies demonstrate cross-reactivity with human, mouse, and rat TOB1 . This multi-species reactivity reflects the high conservation of the sequence surrounding the Ser164 phosphorylation site across these mammalian species.

The conservation of this phosphorylation site indicates its functional importance, as regulatory mechanisms are often evolutionarily preserved. When designing experiments with different model systems, this cross-reactivity is advantageous as it allows researchers to use the same antibody across human samples and rodent models, facilitating translational research approaches.

When selecting an antibody for your specific research, verify the reactivity spectrum of the particular antibody you intend to use, as minor variations may exist between different commercially available clones and preparations.

How does TOB1 phosphorylation relate to its function in cell cycle regulation?

TOB1 functions primarily as a tumor suppressor by inhibiting cell cycle progression. In its unphosphorylated state, TOB1 effectively suppresses proliferation through several mechanisms:

• Negative regulation of Cyclin D1 expression, a critical promoter of G1/S phase transition

• Promotion of mRNA deadenylation, which affects the stability of growth-promoting transcripts

• Interaction with various cell cycle regulatory proteins

When TOB1 becomes phosphorylated at Ser164, its antiproliferative activity is significantly inhibited . This phosphorylation essentially neutralizes TOB1's tumor suppressor function, potentially leading to dysregulated cell proliferation. This relationship between phosphorylation state and functional activity explains why increased phosphorylation of TOB1 is frequently observed in aggressive cancers and correlates with poor clinical outcomes .

The balance between phosphorylated and unphosphorylated TOB1 appears to be a critical determinant in cell cycle regulation, with phosphorylation at Ser164 serving as a molecular switch that modulates TOB1's growth-suppressive properties.

What is the subcellular localization of phosphorylated TOB1?

The subcellular localization of phosphorylated TOB1 exhibits interesting patterns that appear to be tissue-specific and disease-context dependent. Research has revealed substantial differences between normal tissues and cancer specimens:

In normal tissues:

• TOB1 is predominantly located in the nucleus (92.4% nuclear vs. 7.6% cytoplasmic)

• Phosphorylated TOB1 (p-TOB1) is primarily detected in the cytoplasm (63.6% cytoplasmic vs. 36.4% nuclear)

In gastric cancer tissues:

This nuclear accumulation of phosphorylated TOB1 in cancer cells correlates with poor differentiation, deep tumor invasion, and high TNM stage . Interestingly, TOB1's antiproliferative activity appears to be dependent on its nuclear retention, yet phosphorylation within the nucleus may interfere with its tumor suppressor function. This paradox helps explain why increased nuclear p-TOB1 correlates with aggressive tumor behavior and poor prognosis in certain cancers.

How can I optimize detection of phospho-TOB1 (Ser164) in different tissue types?

Optimizing detection of phospho-TOB1 (Ser164) across different tissue types requires careful consideration of several critical factors:

Tissue Preservation and Processing:

• For formalin-fixed, paraffin-embedded (FFPE) tissues, the quality of antigen retrieval is crucial. Test both citrate buffer (pH 6.0) and Tris-EDTA buffer (pH 9.0) to determine optimal conditions for your specific tissue type .

• Limit fixation time to 24 hours when possible, as extended fixation can lead to excessive cross-linking that may mask the phospho-epitope.

• For frozen tissues, consider acetone or methanol fixation, which may better preserve phospho-epitopes compared to formalin fixation.

Phosphatase Inhibition:

• Include phosphatase inhibitors in all buffers during tissue collection and processing to prevent dephosphorylation.

• Rapid tissue processing is essential, as delays can result in loss of phosphorylation due to endogenous phosphatase activity.

Antibody Optimization:

• Perform antibody titration experiments to determine the optimal concentration that provides maximum specific signal with minimal background.

• For IHC applications, test dilutions ranging from 1:100 to 1:300 as recommended by manufacturers .

Signal Amplification and Detection:

• For tissues with low expression levels, consider using signal amplification systems like tyramide signal amplification (TSA).

• When using DAB-based detection, optimize development time to prevent signal saturation while maintaining sensitivity.

Essential Controls:

• Include positive controls (tissues known to express high levels of phospho-TOB1, such as certain cancer samples).

• Incorporate negative controls, including phosphatase-treated serial sections to confirm phospho-specificity.

• Consider dual staining with both phospho-specific and total TOB1 antibodies to calculate the phosphorylation ratio, which is often more informative than absolute levels.

What are the key considerations for using Phospho-TOB1 (Ser164) Antibody in cancer research?

When employing Phospho-TOB1 (Ser164) Antibody in cancer research, several important considerations should guide your experimental design and interpretation:

Tumor Heterogeneity Assessment:

• Cancer tissues display significant heterogeneity. Consider using tissue microarrays (TMAs) or analyzing multiple regions of each tumor to account for this variability .

• The expression and phosphorylation of TOB1 may vary between tumor core and invasive front, requiring spatial sampling strategies.

Clinicopathological Correlation:

• Analyze phospho-TOB1 levels in relation to established clinical parameters such as tumor stage, grade, and patient survival.

• Different cancer types may show variable relationships between phospho-TOB1 and prognosis. For example, increased nuclear p-TOB1 is an independent prognostic factor specifically for intestinal type gastric cancer but not diffuse type .

Subcellular Localization Analysis:

• The nuclear versus cytoplasmic distribution of phospho-TOB1 is altered in cancer cells and appears to have prognostic significance .

• Use careful subcellular fractionation methods or co-staining with nuclear markers to accurately assess this distribution.

Signaling Pathway Context:

• TOB1 is regulated by EGFR/HER2 signaling pathways, which are frequently dysregulated in various cancers.

• Consider analyzing phospho-TOB1 in relation to the activation status of these pathways, especially in breast and gastric cancers where these pathways are often aberrantly activated.

Functional Validation Approaches:

• Complement expression studies with functional assays to determine the biological consequences of TOB1 phosphorylation.

• Consider using phospho-mimetic (S164D) and phospho-deficient (S164A) TOB1 mutants to model the functional effects of phosphorylation in cancer cells.

How does nuclear vs. cytoplasmic localization of phosphorylated TOB1 correlate with clinical outcomes?

The subcellular distribution of phosphorylated TOB1 has emerged as a significant prognostic indicator in cancer research:

Distribution Patterns and Clinical Correlations:

• In normal gastric tissue, p-TOB1 is predominantly cytoplasmic (63.6% cytoplasmic vs. 36.4% nuclear) .

• In contrast, gastric cancer cells show a striking redistribution, with p-TOB1 accumulating primarily in the nucleus (66.0% nuclear vs. 34.0% cytoplasmic) .

• This nuclear accumulation of p-TOB1 in gastric cancer positively correlates with:

  • Poorly differentiated tumors (G3 and G4)

  • Deep tumor invasion (T3 and T4)

  • High TNM stage (III and IV)

Prognostic Significance:

Functional Implications:

These findings emphasize that both the phosphorylation status and subcellular localization of TOB1 must be considered together when evaluating its role as a prognostic biomarker in cancer.

What are the recommended methods for differentiating between phosphorylated and non-phosphorylated TOB1 in experimental settings?

Several complementary approaches can be employed to effectively differentiate between phosphorylated and non-phosphorylated TOB1:

Antibody-Based Detection Methods:

• Parallel Western Blotting: Use phospho-specific antibodies that recognize TOB1 only when phosphorylated at Ser164, alongside antibodies against total TOB1. This allows calculation of the phosphorylation ratio .

• Phos-tag™ SDS-PAGE: This specialized gel system incorporates phosphate-binding molecules that retard the migration of phosphorylated proteins, causing a more pronounced mobility shift that helps distinguish phosphorylated from non-phosphorylated forms.

• 2D Gel Electrophoresis: Separate proteins first by isoelectric point and then by molecular weight, which can resolve different phosphorylated states of TOB1.

Enzymatic Treatment Controls:

• Lambda Phosphatase Treatment: Treat duplicate samples with lambda phosphatase to remove phosphate groups and compare with untreated samples. The phospho-specific signal should disappear after phosphatase treatment, confirming specificity .

• Kinase and Phosphatase Modulators: Treat cells with ERK inhibitors or phosphatase inhibitors to experimentally modulate TOB1 phosphorylation status and validate antibody specificity.

Genetic Approaches:

• Site-Directed Mutagenesis: Generate S164A (prevents phosphorylation) and S164D (mimics phosphorylation) TOB1 mutants as negative and positive controls, respectively.

• Expression Systems: Express wild-type and mutant TOB1 in cell lines to create defined control samples with known phosphorylation states.

Cell Stimulation Experiments:

• Growth Factor Treatment: Stimulate cells with EGF to activate ERK signaling and increase TOB1 phosphorylation at Ser164 as a positive control condition.

• Time-Course Analysis: Monitor phosphorylation dynamics following stimulation to establish temporal patterns that can help distinguish specific phosphorylation events.

Combining multiple approaches provides the most robust differentiation between phosphorylated and non-phosphorylated TOB1 in experimental settings, enhancing confidence in your results.

How can I validate the specificity of Phospho-TOB1 (Ser164) Antibody in my experimental system?

Thorough validation of Phospho-TOB1 (Ser164) Antibody specificity is crucial for ensuring reliable research results. A comprehensive validation approach should include:

Genetic Validation Strategies:

• siRNA/shRNA Knockdown: Reduce TOB1 expression using RNA interference and confirm decreased signal intensity with both phospho-specific and total TOB1 antibodies.

• CRISPR/Cas9 Knockout: Generate TOB1 knockout cell lines as definitive negative controls. Complete absence of signal in knockout cells strongly supports antibody specificity.

• Phospho-Site Mutagenesis: Express TOB1 with Ser164 mutated to alanine (S164A) to prevent phosphorylation. The phospho-specific antibody should not detect this mutant form, confirming site-specificity .

Biochemical Validation Approaches:

• Peptide Competition Assay: Pre-incubate the antibody with excess phosphorylated peptide containing pSer164 and separately with non-phosphorylated peptide. The phospho-peptide should block specific signal, while the non-phospho peptide should not affect detection.

• Phosphatase Treatment: Treat duplicate samples with lambda phosphatase to remove phosphate groups. Loss of signal after phosphatase treatment confirms phospho-specificity .

• Molecular Weight Verification: Confirm that the detected band appears at the expected molecular weight for TOB1 (~38 kDa).

Multiple Antibody Validation:

• Independent Antibody Clones: Compare results using different antibody clones targeting the same phospho-epitope. Consistent results increase confidence in specificity.

• Monoclonal vs. Polyclonal Comparison: When available, compare results between monoclonal and polyclonal antibodies directed against phospho-Ser164. Concordant results strengthen validation.

Application-Specific Controls:

• Western Blotting: Include positive controls (e.g., EGF-stimulated cells) and negative controls (e.g., serum-starved cells) with known phosphorylation status .

• Immunohistochemistry/Immunofluorescence: Compare staining patterns with known TOB1 localization data and include isotype control antibodies to assess non-specific binding .

• Secondary Antibody-Only Controls: Omit primary antibody to assess background from secondary antibody.

Through these rigorous validation steps, you can establish high confidence in the specificity of your Phospho-TOB1 (Ser164) Antibody, ensuring reliable and reproducible research results.

What signaling pathways regulate TOB1 phosphorylation at Ser164?

TOB1 phosphorylation is regulated by several interconnected signaling pathways, with particular emphasis on those relevant to Ser164 phosphorylation:

MAPK/ERK Pathway:

• The MAPK/ERK cascade represents the primary pathway responsible for TOB1 phosphorylation at Ser164.

• ERK1 and ERK2 directly phosphorylate TOB1, with this modification inhibiting TOB1's antiproliferative activity .

• Activation of this pathway through growth factor stimulation (e.g., EGF) leads to increased TOB1 phosphorylation, effectively neutralizing its tumor suppressor function.

HER2/EGFR Signaling:

• TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, which are upstream activators of the MAPK/ERK pathway .

• In cancer contexts, particularly breast cancer, increased HER2 signaling correlates with higher levels of phosphorylated TOB1.

• This relationship is particularly relevant given that HER2 and EGFR are frequently overexpressed or aberrantly activated in various cancers.

Cell Cycle-Related Kinases:

• Cdc7 kinase has been reported to phosphorylate TOB1, which affects its stability by preventing Cul4-DDB1 Cdt2-dependent degradation .

• This mechanism primarily affects TOB1 protein levels rather than directly inhibiting its function, representing an additional layer of regulation.

Regulatory Phosphatases:

• Various protein phosphatases, potentially including PP2A, may counteract kinase activity by dephosphorylating TOB1.

• The balance between kinase and phosphatase activities determines the net phosphorylation status of TOB1 at Ser164.

• Dysregulation of specific phosphatases in cancer contexts may contribute to increased phospho-TOB1 levels.

Understanding these regulatory pathways provides valuable context for interpreting phospho-TOB1 data and identifies potential intervention points for modulating TOB1 activity in research or therapeutic contexts.

How does phosphorylation at Ser164 affect TOB1's interaction with other proteins?

Phosphorylation of TOB1 at Ser164 significantly alters its protein-protein interactions, fundamentally affecting its function as a tumor suppressor:

Interactions with mRNA Regulation Machinery:

• Unphosphorylated TOB1 effectively binds to the Ccr4-Not deadenylase complex to promote mRNA deadenylation and subsequent degradation of growth-promoting transcripts.

• Phosphorylation at Ser164 reduces TOB1's interaction with this complex, inhibiting its mRNA deadenylation activity.

• This alteration can lead to stabilization of growth-promoting mRNAs, including Cyclin D1, potentially promoting cell proliferation.

Nuclear Transport Interactions:

• Phosphorylation may enhance TOB1's association with nuclear export machinery, promoting its translocation from the nucleus to the cytoplasm.

• Since nuclear localization of TOB1 is essential for its antiproliferative activity, this nuclear export effectively inhibits its tumor suppressor function .

• Experimental evidence supports this model, as mutations in TOB1's nuclear export signal enhance its antiproliferative effects .

Cell Cycle Regulatory Interactions:

• TOB1 interacts with various cell cycle regulators, with its phosphorylation state modulating these interactions.

• Phosphorylation at Ser164 appears to disrupt TOB1's ability to negatively regulate Cyclin D1 expression, a key cell cycle promoter.

• This disruption contributes to increased cell proliferation, consistent with observations in cancer contexts.

Protein Stability Regulation:

• TOB1 is regulated by ubiquitination and subsequent degradation via the 26S Proteasome.

• The ubiquitin ligases SCF-Skp2, CRN7, and Cul4-DDB1 Cdt2 have been reported to ubiquitinate TOB1 .

• Phosphorylation at Ser164 may influence these interactions, potentially affecting TOB1 stability and turnover.

These altered protein interactions collectively contribute to the inhibition of TOB1's tumor suppressor function when phosphorylated, providing mechanistic insight into how this post-translational modification impacts cancer progression.

What are the challenges in interpreting phospho-TOB1 levels in heterogeneous tumor samples?

Interpreting phospho-TOB1 levels in heterogeneous tumor samples presents several significant methodological and analytical challenges:

Tumor Heterogeneity Considerations:

Stromal Contamination Effects:

• Tumor samples invariably contain not only cancer cells but also stromal cells, immune cells, and vasculature.

• These non-tumor cells may express TOB1 with different phosphorylation patterns.

• Techniques such as laser capture microdissection or computational deconvolution of bulk tissue data can help isolate cancer cell-specific signals.

Phosphorylation Preservation Issues:

• Phosphorylation is a labile modification that can be rapidly lost during tissue collection, fixation, and processing.

• Delays in fixation or inadequate phosphatase inhibition can lead to dephosphorylation and false-negative results.

• Standardized protocols for rapid tissue processing with phosphatase inhibitors are essential for reliable phospho-TOB1 assessment .

Quantification Methodology Limitations:

• Semi-quantitative methods like IHC scoring have inherent subjectivity and may not linearly correlate with actual phosphorylation levels.

• The threshold for "positive" versus "negative" staining can significantly impact results and should be standardized.

• Digital image analysis can help standardize quantification but requires careful validation.

Context-Dependent Significance Assessment:

• The significance of phospho-TOB1 levels depends on multiple contextual factors including total TOB1 expression, subcellular localization, and tumor type.

• For example, increased nuclear phospho-TOB1 is an independent prognostic factor specifically for intestinal type gastric cancer, but not for diffuse type .

• The ratio of phospho-TOB1 to total TOB1 may be more informative than absolute phospho-TOB1 levels.

Addressing these challenges requires integrated approaches combining multiple techniques, careful sample handling, and comprehensive data analysis to ensure accurate interpretation of phospho-TOB1 levels in heterogeneous tumor contexts.

How do different fixation methods affect the detection of phospho-TOB1 in tissue samples?

Different fixation methods can significantly impact the detection of phospho-TOB1 in tissue samples, influencing both sensitivity and specificity of results:

Formalin Fixation and Paraffin Embedding (FFPE):

• Advantages: Excellent morphological preservation and stable long-term storage.

• Challenges: Formalin creates protein cross-links that can mask the phospho-epitope around Ser164.

• Optimization Strategies:

  • Limit fixation time to 12-24 hours when possible.

  • Optimize antigen retrieval methods, testing both citrate buffer (pH 6.0) and Tris-EDTA (pH 9.0).

  • Heat-induced epitope retrieval (HIER) is typically more effective than proteolytic retrieval for phospho-epitopes .

Frozen Tissue Methods:

• Cold Acetone Fixation:

  • Advantages: Minimal protein cross-linking and good preservation of phospho-epitopes.

  • Challenges: Less optimal morphology compared to FFPE samples.

  • Recommendation: Fix for 10 minutes at -20°C; particularly suitable for immunofluorescence detection of phospho-TOB1.

• Methanol Fixation:

  • Advantages: Good for preserving phospho-epitopes with less harsh effects than formaldehyde.

  • Challenges: Can extract membrane lipids and coagulate proteins rather than cross-linking them.

  • Application: Especially useful for cell-based studies of phospho-TOB1.

Critical Factors Across All Fixation Methods:

• Time to Fixation:

  • Rapid fixation after tissue collection is crucial to prevent phosphatase activity.

  • Ideally, tissues should be fixed or frozen within 20 minutes of collection to preserve phosphorylation status .

• Phosphatase Inhibitor Use:

  • Include phosphatase inhibitors in all buffers during tissue collection and processing.

  • Cocktails containing sodium fluoride, sodium orthovanadate, and β-glycerophosphate are particularly effective for preserving phosphorylation.

• Temperature Control:

  • Keep samples cold (4°C) during collection and processing to minimize phosphatase activity.

• Fixative pH:

  • Neutral buffered formalin (pH 7.0-7.4) is preferred over acidic formulations.

  • Acidic conditions can accelerate dephosphorylation of many phospho-epitopes.

The optimal fixation method may depend on your specific application and the particular phospho-TOB1 (Ser164) antibody being used. Testing multiple conditions with appropriate controls is recommended when establishing a new detection protocol.

What are the best practices for quantifying phospho-TOB1 (Ser164) in Western blot analysis?

Accurate quantification of phospho-TOB1 (Ser164) by Western blot analysis requires meticulous attention to several methodological aspects:

Sample Preparation Optimization:

• Effective Lysis Conditions:

  • Use ice-cold lysis buffer containing phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate).

  • Process samples rapidly to minimize dephosphorylation by endogenous phosphatases.

• Protein Quantification and Loading:

  • Use reliable protein quantification methods (BCA or Bradford assay) to ensure equal loading.

  • Typically load 20-50 μg total protein per lane for optimal detection of phospho-TOB1.

  • Include loading controls to verify equal protein transfer.

Electrophoresis and Transfer Considerations:

• Gel Percentage Selection:

  • Use 10-12% polyacrylamide gels for optimal resolution of TOB1 (~38 kDa) .

• Transfer Optimization:

  • Wet transfer is generally preferred for phosphoproteins.

  • Add 0.01% SDS to transfer buffer to enhance transfer efficiency of phosphoproteins.

  • Consider using PVDF membranes for better protein retention and signal-to-noise ratio.

Immunoblotting Protocol Refinement:

• Blocking Optimization:

  • BSA-based blocking buffers are generally preferred over milk for phospho-specific antibodies.

  • Milk contains casein with phospho-epitopes that may compete with target detection.

• Antibody Incubation:

  • Follow manufacturer's recommended dilution (typically 1:500 - 1:2000) .

  • Incubate primary antibody in solution containing phosphatase inhibitors.

  • Overnight incubation at 4°C often yields optimal results for phospho-specific antibodies.

Essential Controls for Validation:

• Normalization Strategy:

  • Probe for phospho-TOB1 first, then strip and reprobe for total TOB1.

  • Calculate the phospho-TOB1/total TOB1 ratio to account for variations in total protein expression.

  • This normalization is critical as changes in phosphorylation can be independent of changes in total protein level.

• Positive and Negative Controls:

  • Include samples with known high phospho-TOB1 levels (e.g., EGF-stimulated cells).

  • Include phosphatase-treated samples as negative controls to validate specificity.

Quantification Methodology:

• Digital Image Analysis:

  • Use specialized software (ImageJ, Image Lab, etc.) for densitometric analysis.

  • Ensure images are not saturated by capturing exposure series.

  • Subtract background signal from each band measurement.

• Statistical Analysis:

  • Perform experiments in at least three biological replicates.

  • Normalize data to control conditions for each experiment before combining datasets.

  • Apply appropriate statistical tests to determine significance of observed changes.

By following these best practices, researchers can achieve accurate and reproducible quantification of phospho-TOB1 (Ser164) in Western blot analysis, providing reliable data for advancing our understanding of TOB1 regulation in various biological contexts.